/

/

Master Trial Index (All Years)

/

REGARD-VAP

Category

Infectious Diseases & Antimicrobial Stewardship

Full Summary

https://app.notion.com/p/3ab1a8cd5af18146a581f40739b4ca4d

Journal

Lancet Respir Med

Takeaway

Individualized short-course antibiotics for VAP noninferior, cut antibiotic side effects from 38% to 8%.

Verdict

Positive

Year

2024

myICUnotes © 2026 by Dr Abhijeet Anand is licensed under CC BY-NC-SA 4.0. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/